- Home
- HFFG vs AGEN Comparison
HFFG vs AGEN Comparison
Compare HFFG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HFFG | AGEN |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.8M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | HFFG | AGEN |
|---|---|---|
| Price | $2.14 | $3.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 112.7K | ★ 901.2K |
| Earning Date | 03-12-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,225,541,000.00 | $106,829,000.00 |
| Revenue This Year | $4.36 | $23.68 |
| Revenue Next Year | $3.35 | $23.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $1.70 | $1.38 |
| 52 Week High | $4.93 | $7.34 |
Technical Indicators
Market Signals| Indicator | HFFG | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 36.58 |
| Support Level | $2.11 | $3.12 |
| Resistance Level | $2.23 | $3.55 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 17.16 | 2.86 |
Price Performance
Historical ComparisonAbout HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).